Bevacizumab Biosimilar IBI305 plus sintilimab Clinical Trials
2 recruitingDrug
Showing 1–2 of 2 trials
Recruiting
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-resectable
Ze-yang Ding, MD300 enrolled2 locationsNCT05713994
Recruiting
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-resectable
Tongji Hospital300 enrolled4 locationsNCT05717738